The FDA granted fast track designation to KT-621 for treating patients with moderate to severe eosinophilic asthma, according ...

For patients with moderate to severe eosinophilic asthma or oral corticosteroid (OCS)-dependent asthma and inadequate disease control, the decision to add biologic therapy is based on the patient’s ...

Sublingual Immunotherapy Stops Onset and Worsening of Asthma The French EfficAPSI study confirmed that sublingual liquid immunotherapy or "desensitization" reduces the risks for asthma onset and the ...

Machine learning models may help identify risk for asthma among children with atopic dermatitis in early life.

Inhaled anti-TSLP asthma therapy reduced FeNO and showed good safety in early trials. Find out what this means for asthma ...

Add Yahoo as a preferred source to see more of our stories on Google. APG808 was well-tolerated and there were no severe adverse events. Credit: Explode via Shutterstock. (Explode via Shutterstock.) ...

Blood eosinophil count and fractional exhaled nitric oxide (FeNO) play an important role in selecting biological therapies for severe asthma. This analysis of patient-level data pooled across 22 ...

The AIRQ effectively identifies asthma exacerbation risk at 3 months and 12 months among patients with varying levels of asthma severity.

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track ...

In the U.S., 25 million people are affected by asthma. That’s roughly 1 in 13 adults and children. Asthma can be mild or severe. Some people with asthma have symptoms every day. Others have symptoms ...

An asthma attack makes breathing hard, and it can be triggered by allergens or intense emotions. It is important to use a quick-relief inhaler at the first sign of an asthma attack. You can avoid ...